|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM323934145 |
| 003 |
DE-627 |
| 005 |
20231225185236.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2021.108723
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1079.xml
|
| 035 |
|
|
|a (DE-627)NLM323934145
|
| 035 |
|
|
|a (NLM)33838340
|
| 035 |
|
|
|a (PII)S1521-6616(21)00060-7
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Kenig, Ariel
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 10.06.2021
|
| 500 |
|
|
|a Date Revised 21.12.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2021 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Severe acute respiratory syndrome coronavirus 2 infected patients, receiving background anti-CD20 therapy, were treated with convalescent plasma or plasma-based products. Eight patients were included in the study, presenting with prolonged disease course and delayed viral clearance. CP/plasma-based products were offered as an add-on therapy to standard medical treatment. All patients showed remarkable clinical and laboratory improvement. In addition, polymerase chain reaction from nasopharyngeal swabs rapidly converted to negative following plasma administration. This study emphasizes the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion
|
| 650 |
|
4 |
|a Case Reports
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a B-cells
|
| 650 |
|
4 |
|a COVID-19
|
| 650 |
|
4 |
|a Convalescent plasma
|
| 650 |
|
4 |
|a Rituximab
|
| 650 |
|
4 |
|a SARS-CoV-2
|
| 650 |
|
7 |
|a Antibodies, Viral
|2 NLM
|
| 650 |
|
7 |
|a Antineoplastic Agents, Immunological
|2 NLM
|
| 650 |
|
7 |
|a Rituximab
|2 NLM
|
| 650 |
|
7 |
|a 4F4X42SYQ6
|2 NLM
|
| 700 |
1 |
|
|a Ishay, Yuval
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Kharouf, Fadi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rubin, Limor
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 227(2021) vom: 15. Juni, Seite 108723
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:227
|g year:2021
|g day:15
|g month:06
|g pages:108723
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2021.108723
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 227
|j 2021
|b 15
|c 06
|h 108723
|